Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2001 1
2003 1
2007 1
2008 2
2009 4
2011 3
2012 8
2013 6
2014 7
2015 16
2016 13
2017 7
2018 8
2019 21
2020 29
2021 31
2022 28
2023 21
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Metastatic urothelial carcinoma.
Knowles M, Dyrskjøt L, Heath EI, Bellmunt J, Siefker-Radtke AO. Knowles M, et al. Cancer Cell. 2021 May 10;39(5):583-585. doi: 10.1016/j.ccell.2021.04.012. Cancer Cell. 2021. PMID: 33974855 Free article. Review.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Loriot Y, et al. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. N Engl J Med. 2019. PMID: 31340094 Clinical Trial.
METHODS: In this open-label, phase 2 study, we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecified FGFR alterations. ...CONCLUSIONS: The use of erdafitinib was associated with an objective tumor res …
METHODS: In this open-label, phase 2 study, we enrolled patients who had locally advanced and unresectable or metastatic urothelia …
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. Yuen KC, et al. Nat Med. 2020 May;26(5):693-698. doi: 10.1038/s41591-020-0860-1. Epub 2020 May 11. Nat Med. 2020. PMID: 32405063 Free PMC article.
Here we analyzed circulating pIL-8 and IL8 gene expression in peripheral blood mononuclear cells and tumors of patients treated with atezolizumab (anti-PD-L1 monoclonal antibody) from multiple randomized trials representing 1,445 patients with metastatic urothelial …
Here we analyzed circulating pIL-8 and IL8 gene expression in peripheral blood mononuclear cells and tumors of patients treated with atezoli …
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J. Sheng X, et al. Clin Cancer Res. 2021 Jan 1;27(1):43-51. doi: 10.1158/1078-0432.CCR-20-2488. Epub 2020 Oct 27. Clin Cancer Res. 2021. PMID: 33109737 Clinical Trial.
PURPOSE: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in patients with HER2(+) locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies. ...
PURPOSE: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in p …
Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications.
Vassiliou V, Katsila T, Sodergren SC, Kardamakis D. Vassiliou V, et al. Anticancer Res. 2022 Aug;42(8):3767-3778. doi: 10.21873/anticanres.15867. Anticancer Res. 2022. PMID: 35896266 Review.
It exhibits high mortality and morbidity rates and is usually diagnosed at a late, incurable stage, carrying a poor prognosis. Local symptoms in patients with metastatic urothelial carcinoma (mUC) have an adverse impact on quality of life (QoL) and are associ …
It exhibits high mortality and morbidity rates and is usually diagnosed at a late, incurable stage, carrying a poor prognosis. Local symptom …
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
Castro-Alonso FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, Bourlon MT. Castro-Alonso FJ, et al. Oncology (Williston Park). 2023 Jun 12;37(6):256-261. doi: 10.46883/2023.25920998. Oncology (Williston Park). 2023. PMID: 37343207 Free article.
The landscape of immunotherapy in metastatic urothelial carcinoma.
Teo MY, Iyer G. Teo MY, et al. Curr Opin Urol. 2019 Nov;29(6):643-648. doi: 10.1097/MOU.0000000000000676. Curr Opin Urol. 2019. PMID: 31567441 Review.
PURPOSE OF REVIEW: This review provides an overview of clinical trials recently completed or currently ongoing evaluating the role of checkpoint blockade in metastatic urothelial carcinoma. RECENT FINDINGS: In 2016, five immunotherapy agents were approved for …
PURPOSE OF REVIEW: This review provides an overview of clinical trials recently completed or currently ongoing evaluating the role of checkp …
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Gevaert T, Cimadamore A, Montironi R, Eckstein M. Gevaert T, et al. Curr Drug Targets. 2021;22(2):162-170. doi: 10.2174/1389450121666200510015216. Curr Drug Targets. 2021. PMID: 32386490 Review.
Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. ...
Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or meta …
Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N, Chahine C, Kordahi M, Felefly T, Kourie HR, Saleh K. Khalife N, et al. Immunotherapy. 2021 Aug;13(11):953-964. doi: 10.2217/imt-2021-0042. Epub 2021 Jun 29. Immunotherapy. 2021. PMID: 34184561 Review.
Platinum-based chemotherapy is the first-line treatment in locally advanced or metastatic urothelial carcinoma. Immune checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma as second-line treatment …
Platinum-based chemotherapy is the first-line treatment in locally advanced or metastatic urothelial carcinoma. Immune …
177 results